Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
16. Dezember 2021 08:59 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
01. Dezember 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
22. November 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
10. November 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
Announces Intent to Develop TSC to Treat Hypoxic TumorsAltitude Trial Expected to Commence in November 2021ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. ...
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
28. Oktober 2021 07:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Issues Letter to Shareholders
09. September 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
08. September 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division
30. August 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND Fourth FDA Division to Clear TSC IND CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion...
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
11. August 2021 07:32 ET
|
Diffusion Pharmaceuticals Inc.
Reports Improved Outcomes in Phase 1b COVID-19 Study and Positive Trend in Peripheral Oxygenation in Phase 1b TCOM StudyExpects to Announce Initial Indication and Regulatory Pathway in Fourth Quarter...
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
30. Juni 2021 07:35 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...